Pidilizumab

Pidilizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	DLL1
Clinical data
ATC code	none;
Identifiers
CAS Number	1036730-42-3 ;
ChemSpider	none;
UNII	B932PAQ1BQ;
KEGG	D10390;
Chemical and physical data
Formula	C6424H9920N1704O2002S48
Molar mass	144594.83 g·mol−1

Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.[1][2] Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule.[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.

Clinical trials

It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.[4] A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. A phase I/II open label study in pediatric patients with a rare form of brain cancer, diffuse intrinsic pontine glioma, found improvement in overall survival compared to expected outcome. An add-on trial for multiple myeloma is ongoing.[5]

References

Westin; et al. (2014). "Safety and Activity of PD1 Blockade by Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: a Single Group, Open-label, Phase 2 Trial". Lancet Oncol. 15: 69–77. doi:10.1016/S1470-2045(13)70551-5. PMC 3922714. PMID 24332512.
Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.
http://www.fiercebiotech.com/story/anti-pd-1-well-no-says-medivation-partial-hold-forces-halt-pivotal-cancer-s/2016-01-26
Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data. Sept 2011
"Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2015-08-22.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Westin2014-1] Westin; et al. (2014). "Safety and Activity of PD1 Blockade by Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: a Single Group, Open-label, Phase 2 Trial". Lancet Oncol. 15: 69–77. doi:10.1016/S1470-2045(13)70551-5. PMC 3922714. PMID 24332512.

[2] Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.

[3] ttp://www.fiercebiotech.com/story/anti-pd-1-well-no-says-medivation-partial-hold-forces-halt-pivotal-cancer-s/2016-01-26

[4] Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data. Sept 2011

[5] "Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2015-08-22.